Novo Nordisk A/S
Company & revenue
About Novo Nordisk A/S
Financial breakdown: year ended 2025-12-31
Who they are
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
Brands & revenue mix
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Customer concentrationPREMIUM
Novo Nordisk does not disclose specific major customers by name. In its 2025 Form 20-F, the company notes that it records estimates for sales deductions including rebates and discounts to government agencies, wholesalers, health insurance companies, and managed healthcare organizations, but does not report concentration figures for these entities.
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
62
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
73
Strong
Financial Strength
62
Business Quality / Moat
72
Management
100
Growth Quality
51
Risk / Durability
94
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
70
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
66/100
Building Historical Record
Model Score 66/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Valuation scores attractively
- •Recent buyback activity is present
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for NVO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can NVO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is NVO's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is NVO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •Is NVO's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of NVO's score?
Essential Investment Snapshot
Wall Street Score
62
Opportunity Score
70
Market Cap
$165.72B
P/E Ratio
9.4
EPS
$3.98
52-Week High
$64.16
52-Week Low
$35.12
Beta
0.35
Intrinsic Value
$153.36
Analyst Target
$47.00
Shares Outstanding
4.45B
Total Revenue
$50.03B
Total Debt
$21.28B
Dividend Yield
4.72%
Liquidation Value / Share
$7.55
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NVO
Detected from reported data — verify before acting.Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on NVO.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care di.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
59
Jul 24, 2026
Change
+2.6
points
Current Score
62
Oct 1, 2026
Category Changes
NVO increased 2.6 points because Revenue improved by 2.3 points, Asset improved by 3.8 points, Capital improved by 11 points.
Positive Contributors
- + Revenue improved by 2.3 points
- + Asset improved by 3.8 points
- + Capital improved by 11 points
- + Management improved by 5 points
- + Valuation improved by 17.5 points
- + Buffett improved by 3.5 points
Projected Score
Projected Score
60
Projected Change
-2.0%
Preliminary comparable-period financial changes suggest decline of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$37.32
Intrinsic Value
$153.36
Difference
−$116.04
-75.7% vs IV
Margin of Safety
75.7%
Related Companies
Drug Manufacturers - GeneralNews
NVO DCF Analysis: Intrinsic Value $95 vs Price $38
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial